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Syncytiainal has antiviral activity against herpes simplex virus-1 (HSV-1) and inhibits
dephosphorylation of eIF2α mediated by the HSV-1 protein ICP34.5. We investigated whether salubrinal's
activities in infected cells depend on ICP34.5. An ICP34.5 deletion mutant was as sensitive as wild type HSV-1
to salubrinal inhibition of plaque formation in Vero cells. However, salubrinal induced formation of syncytia
in infected Vero cells, which was enhanced by ICP34.5 mutations. Expression of HSV-1 US11 with immediate
early kinetics, which is known to suppress the effects of ICP34.5 mutations, resulted in slight resistance to
salubrinal in murine embryonic ﬁbroblasts, and substantial resistance in those cells when ICP34.5 was
additionally mutated. ICP34.5 mutations, but not immediate early expression of US11, prevented salubrinal's
ability to increase phosphorylation of eIF2α during HSV-1 infection of Vero cells. Taken together, our data
indicate that salubrinal has both ICP34.5-dependent and -independent activities in HSV-1 infected cells.
© 2008 Elsevier Inc. All rights reserved.Introduction
Virus infection elicits an innate antiviral response in which the
host cell attempts to slow or stop viral replication (Schneider and
Mohr, 2003). Like many viruses, HSV-1 encodes multiple gene
products to counter these innate cellular defense mechanisms,
allowing the virus to overcome the antiviral response of the infected
cell (Schneider and Mohr, 2003). One major pathway employed by
cells to inhibit viral replication is to phosphorylate the translation
initiation factor eIF2α, which results in the global shutoff of
translation and thus halts viral replication (Hinnebusch, 2000). HSV-
1 encodes at least two gene products, ICP34.5 and US11, that act to
counter this shutoff of global protein synthesis.l Chemistry and Molecular
Ave, Boston, MA 02115, USA.
oen).
Molecular Genetics, Harvard
oxicology, Dartmouth Medical
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l rights reserved.The viral gene product ICP34.5 mediates the dephosphorylation of
eIF2α by binding protein phosphatase 1α (PP1α) and directing its
activity to eIF2α (Chou and Roizman, 1992; He et al., 1997b; He et al.,
1998). eIF2α dephosphorylation allows viral genes to be translated
although eIF2α kinases, such as PKR, remain active. ICP34.5 is
homologous to the cellular protein GADD34, which can also bind
PP1α and direct the dephosphorylation of eIF2α (Fornace et al., 1989;
Lord et al., 1990; McGeoch and Barnett, 1991).
Additionally, US11, a virally encoded RNA binding protein, can bind
the eIF2α kinase PKR, and inhibit its activity (Cassady and Gross,
2002; Cassady et al., 1998; Mulvey et al., 1999; Poppers et al., 2000).
US11 is necessary to achieve maximal rates of protein synthesis at late
times post infection, likely due to the ability of US11 to inhibit the high
levels of activated PKR present at these times (Mulvey et al., 2003).
US11 is normally expressed as a late gene product, but when it is
ectopically expressed as an immediate early gene product, US11 has
been shown to be able to compensate for ICP34.5 mutations in cells
where ICP34.5 is required for viral replication and protein synthesis
(He et al., 1997a; Mohr and Gluzman, 1996).
The small molecule salubrinal (sal) was identiﬁed in a high
throughput assay for its ability to protect cells from endoplasmic
reticulum (ER) stress induced apoptosis (Boyce et al., 2005). Treatment
of cells with sal increases the level of phosphorylated eIF2α, and this
increase in phosphorylation was attributed to an inhibition of cellular
GADD34-mediated dephosphorylation of eIF2α, rather than an
198 K.F. Bryant et al. / Virology 379 (2008) 197–204increase in eIF2α kinase activity, making sal the ﬁrst inhibitor of a
particular dephosphorylation reaction (Boyce et al., 2005). The sal-
dependent increase in eIF2α phosphorylation accounts for the
resistance to ER stress induced apoptosis, presumably because the
shutoff of translation and the gene expression program that is
activated following eIF2α phosphorylation allow the cell to respond
to and recover from the stress (Boyce and Yuan, 2006).
Given the homology between GADD34 and ICP34.5, the ability of
sal to inhibit ICP34.5-mediated dephosphorylation of eIF2α and to
inhibit HSV-1 replicationwas investigated (Boyce et al., 2005). Lysates
from cells transfected with plasmids expressing ICP34.5 and treated
with sal were inhibited for ICP34.5-mediated dephosphorylation of
eIF2α relative to mock treated transfected cells (Boyce et al., 2005).
Additionally, sal inhibited HSV-1 replication in Vero cells and murine
embryonic ﬁbroblasts with an IC50 of ∼3 μM (Boyce et al., 2005).
Furthermore, sal had dramatically reduced antiviral activity in MEFs
that contain a non-phosphorylatable eIF2α, indicating that phosphor-
ylation of eIF2α is important for the full antiviral activity of sal (Boyce
et al., 2005). However, it is not knownwhether ICP34.5 is required for
the antiviral activity of sal or for the effects of sal on eIF2α during HSV-
1 infection. In this report, we take a genetic approach to investigate
these questions.
Results and discussion
Antiviral activity of salubrinal is independent of ICP34.5 in Vero cells
Sal has previously been shown to have anti-HSV-1 activity that is
dependent on phosphorylatable eIF2α and extracts from sal treated
cells expressing ICP34.5 were inhibited for the dephosphorylation of
eIF2α (Boyce et al., 2005). To investigate whether expression of
ICP34.5 is necessary for the antiviral activity of sal, we performed
plaque reduction assays in Vero cells infected with HSV-1 wild type
strain F; the ICP34.5 mutant R3616, which contains an approximately
1 kb deletion in the gene encoding ICP34.5; or a rescued virus F(R), in
which the 1 kb deletion was restored with wild type strain F
sequences (viruses were kindly provided by J. Chou and B. Roizman
(Chou et al., 1990)). As observed before (Boyce et al., 2005), sal
exhibited antiviral activity, but did not result in complete elimination
of plaque formation by HSV-1 in Vero cells, even at high doses (Fig. 1).Fig. 1. Antiviral activity of sal in plaque reduction assays. Vero cells were treated with
either DMSO-containing vehicle or the indicated concentration of sal for 24 h prior to
infection with 150 pfu of HSV-1 strain F (black lines with diamonds), R3616 (light gray
lines with squares), or F(R) (dark gray lines with triangles). Plaques were allowed to
form for 2–3 days in the presence of the indicated concentration of sal and then were
counted. Data are presented as percent of plaques remaining, relative to treatment with
vehicle alone, at each sal concentration. Error bars represent standard errors of the
mean (n=7 for strain F and R3616 and n=5 for F(R)). There was no signiﬁcant difference
(p values ranging between 0.072–0.97 by Student's t test) between F and R3616 at the
various sal concentrations.Sal treatment reproducibly inhibited plaque formation by all three
viruses similarly (Fig. 1), indicating no dependence on ICP34.5 for the
antiviral activity of sal in Vero cells. Possible explanations for this lack
of ICP34.5 dependence are discussed towards the end of this section.
Salubrinal treatment results in a syncytial phenotype during HSV-1
infection
In the course of these studies, we observed that sal treatment
induced syncytial cytopathic effect (CPE) in HSV-1 infected Vero cells.
Syncytia were not observed in sal treated Vero cells that were mock
infected (Fig. 2, top row). Following infection with strain F at a
multiplicity of infection (MOI) of 3, syncytial CPE was observed upon
treatment with 7.5 μM sal, and nearly encompassed the entire infected
monolayer at 75 μM sal (Fig. 2, second row from top). However,
syncytia were not evident in strain F infected cells that were not
treated with sal. Interestingly, we observed sporadic small syncytia in
untreated R3616-infected Vero cells (example in Fig. 2, third row from
top, left panel, small syncytia indicated by arrows). Treatment with sal
greatly enhanced the formation of syncytia in R3616-infected Vero
cells so that they completely covered the infected monolayer
following treatment with both 7.5 μM and 75 μM sal (Fig. 2, third
row from top, middle and right panels). The effects of sal on syncytia
formation in Vero cells infected with F(R), the virus with the ICP34.5
mutation restored, were similar to those observed in cells infected
with strain F (Fig. 2, compare second row from top with bottom row).
Thus, the more potent induction of syncytial CPE by sal in R3616-
infected Vero cells was due to the ICP34.5 mutation. A similar
enhancement of syncytial CPE induced by sal was observed with
other ICP34.5 mutants (data not shown). Our results suggest that sal
inhibits an activity that normally prevents the formation of syncytia in
HSV-1 infected cells, and this prevention of syncytia formation is
partially dependent on ICP34.5.
ICP34.5 has previously been linked to the syncytial phenotype; a
mutation that results in syncytia formationwas mapped to the region
of the HSV-1 genome containing the ICP34.5 polyadenylation signal
(Romanelli et al., 1991). Additionally, although mediating the depho-
sphorylation of eIF2α is the best characterized activity of ICP34.5
during HSV-1 infection, ICP34.5 has also been implicated as playing a
role in viral egress (Brown et al., 1994; Jing et al., 2004; Jing and He,
2005). Thus, ICP34.5 itself may inhibit syncytia formation, either by
permitting the synthesis of certain late viral proteins or by promoting
viral egress. Therefore, sal may induce syncytia formation in part by
direct or indirect inhibition of ICP34.5. Nevertheless, as sal-induced
syncytia formation is enhanced by the absence of ICP34.5, sal must
also act via some other target to cause this phenotype.
Effect of ectopic expression of IE US11 on the antiviral activity of
salubrinal
Although ICP34.5 was not necessary for the antiviral activity of sal
in Vero cells, these cells are permissive for ICP34.5 mutant virus
replication, leaving the possibility that ICP34.5may be required for the
antiviral activity of sal in cells that are non-permissive for the
replication of ICP34.5 mutants, such as MEFs. We could not directly
test whether the antiviral activity of sal in MEFs depends on ICP34.5
because ICP34.5 null mutant viruses do not replicate in these cells. An
alternate approach was suggested by previous studies that showed
that expressing the late viral protein US11 as an immediate early gene
(IE US11) can rescue the ICP34.5mutant phenotypes of decreased viral
replication and decreased viral protein synthesis in cells such as MEFs
that are non-permissive for ICP34.5 mutant replication (He et al.,
1997a; Mohr and Gluzman, 1996). IE US11 viruses are able to inhibit
the phosphorylation of eIF2α by interacting with and antagonizing
the activity of PKR. We hypothesized that if inhibiting ICP34.5-
mediated dephosphorylation was responsible for the antiviral activity
Fig. 3. Western blot analysis of US11 expression. MEF cells were either mock infected
(lane 1), infectedwith KOS at anMOI of 10 (lanes 2–7) or infectedwith NM1 at anMOI of
10 (lanes 8–13) and harvested at 2, 4, 6, 9, 12, or 24 h post infection, as indicated above
the top panel. Proteins in the cell lysates were resolved by SDS-polyacrylamide gel
electrophoresis and transferred to a PVDF membrane. The membrane was cut and the
bottom half was probed using an antibody against US11 while the membrane from the
top half was probed with an antibody against β-actin to conﬁrm equal loading among
the samples. Puriﬁed recombinant US11 was also tested as a positive control for the
US11 antibody and for migration of the immunoreactive species (lanes 14 and 15).
Fig. 2. Sal induces syncytial HSV-1 infection. Vero cells were treated with either DMSO (left column) or the indicated concentration of sal (two right columns) for 24 h prior to either
mock infection (top row) or infection at a multiplicity of 3 with the indicated virus (bottom three rows). Infection was allowed to proceed for 18 h in the presence of DMSO or the
indicated concentration of sal and the cellular morphology was visualized by phase contrast light microscopy. Regions of small syncytia formation are indicated by arrows. Images
were obtained by photographing with a Nikon Coolpix 4500 digital camera.
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dephosphorylation of eIF2α is not expected to be required for
replication of these mutant viruses.
To address this hypothesis we utilized two different IE US11
viruses, each in a different wild type background. We constructed a
recombinant IE US11 mutant virus in the HSV-1 wild type strain KOS
background using a strategy similar to one previously described
(Mulvey et al., 1999). To generate this mutant, which we named NM1,
we inserted the immediate early ICP27 promoter (Spector et al., 1990)
upstream of the US11 open reading frame. This IE US11 expression
cassette was then inserted into the thymidine kinase (tk) locus of HSV-
1 strain KOS by homologous recombination, and the mutant virus was
selected for loss of TK using acyclovir. The NM1 mutant virus contains
awild typeUS11 locus in addition to the locus encoding the ectopically
expressed IE US11.
We conﬁrmed the IE US11 expression phenotype of NM1 by
western blot analysis (Fig. 3). Vero cells were infected with either KOS
or NM1 for various times and lysates were prepared at the times
indicated to assess US11 expression. In KOS infected cells, a protein
both reacting with anti-US11 antisera and co-migrating with puriﬁed
recombinant US11 (generously provided by Jennifer Baltz; Fig. 3, right
panel) was readily detected starting at 6 h post infection (Fig. 3, top
left panel). In contrast, in NM1 infected cells, this protein was
abundant as early as 2 h post infection (Fig. 3, top left panel),
conﬁrming the IE expression of US11 in this mutant. Equivalentloading of each sample was demonstrated by probing for β-actin (Fig.
3, bottom left panel).
Additionally, we utilized a previously characterized IE US11 virus,
Volney (also known as 34.5RΔSUP; (Mohr et al., 2001)), which is
derived from HSV-1 wild type strain Patton and was generously
Fig. 5. Lack of resistance of the IE US11 virus to sal in Vero cells. Vero cells were treated
with the indicated concentrations of sal for 24 h prior to infectionwith 150 pfu of Patton
(black line with squares), or Volney (gray line with triangles). Plaques were allowed to
form for 2–3 days in the presence of the indicated concentration of sal and were then
counted. Data are presented as the percentage of plaques remaining, relative to the
DMSO treatment, at each sal concentration.
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selected for its ability to replicate in otherwise non-permissive cells
despite not expressing ICP34.5. SUP1 in turn was derived from the
ICP34.5 mutant 5e (also known as SPBg5e), in which both copies of
ICP34.5 were deleted and replaced with β-glucuronidase (Mohr and
Gluzman, 1996). The ICP34.5 mutations of SUP1 were repaired, which
yielded Volney (Mohr et al., 2001). Volney therefore contains wild
type ICP34.5 loci but contains a deletion upstream of the US11 ORF
that places the expression of the endogenous US11 gene under the
control of the adjacent immediate early α47 promoter.
Both sets of IE US11 viruses were slightly resistant to sal in plaque
reduction assays inMEFs relative to their respectivewild type parental
virus (Fig. 4A, B). This slight resistance was highly reproducible. The
difference between the sensitivity of Patton and Volney to sal was
statistically signiﬁcant at both 3 μM (p=0.0415) and 4 μM sal
(p=0.0007) by the Student's t test. The difference between the
sensitivity of KOS and NM1 to sal was also signiﬁcant at both 2 μM
(p=0.0133) and 3 μM sal (p=0.0277). Thus, ectopic immediate early
expression of US11 can confer slight resistance to sal in MEF cells.
In Vero cells, the IE US11 virus Volneywas not measurably resistant
to sal relative towild type HSV-1 (Fig. 5), indicating no effect of ectopic
US11 expression on sal activity in these cells, and thus suggesting that
there is cell type speciﬁcity to the activity of sal. Similar results were
seenwhenwe compared the sensitivity of KOS and NM1 to sal in Vero
cells (data not shown). Additionally, we observed that sal is more
efﬁcacious in MEF cells than in Vero cells (Fig. 4 and Fig. 5), further
suggesting that sal activity has cell type speciﬁcity.Fig. 4. Slight resistance of the IE US11 viruses to sal in MEFs. MEF cells were pretreated
with DMSO or varying concentrations of sal, as indicated, for 24 h prior to infectionwith
150 pfu of (A) Patton (WT, black line with diamonds) and Volney (IE US11 virus, gray line
with squares) or (B) KOS (WT, black line with diamonds) and NM1 (IE US11 virus, gray
line with squares). After 3 days in the presence of sal, viral plaques were quantiﬁed and
results show the percent of plaques remaining, relative to treatment with DMSO alone,
at each sal concentration. Mean values from three separate experiments are shown
(error bars represent standard errors of the mean).The observation that IE expression of US11 conferred at most slight
resistance to sal in the presence of ICP34.5 was somewhat surprising.
Since IE US11 is known to antagonize the activity of the eIF2α kinase
PKR (Cassady and Gross, 2002; Cassady et al., 1998; Mulvey et al.,
1999; Poppers et al., 2000), our observation of minimal resistance to
sal suggests that, in addition to PKR, there may be additional eIF2α
kinases, such as PERK or GCN2, activated during HSV-1 infection of
MEFs that are not inhibited by US11. The eIF2α kinase PERK has been
reported to be activated during HSV-1 infection (Cheng et al., 2005).
PERK is not known to be inhibited by US11, and its activation could be
responsible for the susceptibility to sal of the IE US11 viruses.
However, more recent work has suggested that HSV-1 infection does
not activate PERK (Mulvey et al., 2007).
Resistance of an IEUS11-ICP34.5 double mutant to salubrinal in MEFs
Because IE US11 expression can permit HSV replication in the
absence of ICP34.5 in otherwise non-permissive cells, we investigated
the susceptibility to sal of the IE US11-ICP34.5 double mutant SUP1
(Mohr and Gluzman, 1996) in MEFs. Plaque formation by SUP1 was
substantially resistant to inhibition by sal relative to its wild type
parent, Patton (Fig. 6) and to the single IE US11 mutant, Volney, in
which the ICP34.5 mutation in SUP1 was rescued (Fig. 4 and data notFig. 6. Resistance of SUP1 to sal in MEFs. MEF cells were pretreated with DMSO or
varying concentrations of sal, as indicated, for 24 h prior to infection with 150 pfu of
Patton (WT, black line with diamonds) and SUP1 (IE US11, Δ34.5 virus, gray line with
triangles). After 3 days in the presence of sal, viral plaques were quantiﬁed and results
show the percent of plaques remaining, relative to DMSO treatment alone, at each sal
concentration. Data shown are from a single experiment run in triplicate. Error bars
represent standard errors of the mean.
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shown). Thus, in MEFs, it appears that sal antiviral activity depends on
ICP34.5. The simplest explanation for this result is that ICP34.5 is a
direct target for sal. This interpretation is consistent with our previous
report of inhibition of eIF2α dephosphorylation in lysates of sal-
treated ICP34.5-transfected cells (Boyce et al., 2005). However, less
direct interpretations cannot be excluded.
Salubrinal-mediated increases in eIF2α phosphorylation during HSV-1
infection depend on ICP34.5
Sal has previously been shown to increase eIF2α phosphorylation
during HSV-1 infection (Boyce et al., 2005). Therefore, we investigated
whether ICP34.5 was necessary for this sal-dependent increase. We
performed western blot analyses of phosphorylated and total eIF2α
on lysates from Vero cells that were treated with sal or mock treated
with DMSO, and subsequently either mock infected or infected with
various wild type, ICP34.5 mutant, and IE US11 viruses. The western
blots were quantiﬁed using dilution series to generate standard curves
(Fig. 7A, lanes 19–23), which were used to determine the relativeFig. 7. Effects of salubrinal on eIF2α phosphorylation. (A)Western blot analysis of eIF2α phos
and 18) or DMSO-containing vehicle (-, lanes 1, 3, 5, 7, 9, 11, 13, 15, and 17) for 24 h prior to e
ICP34.5 mutant R3616 (lanes 5 and 6), KOS (lanes 7 and 8), the IE US11mutant NM1 (lanes 9 a
ICP34.5 double mutant SUP1 (lanes 15 and 16), or the ICP34.5mutant 5e (lanes 17 and 18) at a
and resolved by SDS-PAGE. Samples were resolved on duplicate gels andwere immunoblotted
Quantiﬁcation of the western blot data in (A). The dilution series at the right end of each pan
each band on a scanned ﬁlm using Quantity One software (BioRad). The standard curve was
each sample. The level of phosphorylated eIF2αwas normalized to the level of total eIF2α in e
the normalized level of phosphorylated eIF2α in the mock treated, mock infected sample.levels of total eIF2α (which varied relatively little among samples) and
phosphorylated eIF2α in each sample. Results from this quantiﬁcation
indicated that sal treatment increased levels of phophorylated eIF2α
by approximately 8-fold in mock infected Vero cells (Fig. 7B). Sal
treatment resulted in an additional increase in eIF2α phosphorylation
in Vero cells infected with any of three wild type strains of HSV-1
(F, KOS, and Patton) relative to mock treatment (Fig. 7A, top panel,
compare lanes 3 and 4, 7 and 8, and 11 and 12). The increase in
phosphorylation relative to mock treated, mock infected Vero cells
was greater than 30-fold in sal treated cells infected with any of the
three wild type viruses (Fig. 7B).
The amount of phosphorylated eIF2α was high in mock treated
R3616 infected Vero cells (Fig. 7A, top panel, lane 5), as expected due to
the absence of ICP34.5 mediated dephosphorylation, but the amount
of phosphorylated eIF2αwas not further increased upon sal treatment
(Fig. 7A, top panel, lane 6). Moreover, there was more phosphorylated
eIF2α in Vero cells infected with wild type virus that were treated
with sal than in either mock- or sal-treated Vero cells infected with
R3616. Thus, the level of eIF2α phosphorylation is not maximal in
mock treated Vero cells infected with the ICP34.5 mutant R3616, sophorylation. Vero cells were treated with either 75 μM sal (+, lanes 2, 4, 6, 8, 10,12,14,16,
ither mock infection (lanes 1 and 2) or infection with HSV-1 strain F (lanes 3 and 4), the
nd 10), Patton (lanes 11 and 12), the IE US11mutant Volney (lanes 13 and 14), the IE US11,
n MOI of 3 in the presence of DMSO or sal. At 14 h post infection, lysates were prepared
for either total eIF2α (bottom panel) or serine-51 phosphorylated eIF2α (top panel). (B)
el (lanes 19–23) were used to generate a standard curve by determining the intensity of
then used to determine the relative concentration of phosphorylated or total eIF2α in
ach sample. The results are presented as the fold increase in phosphorylation relative to
202 K.F. Bryant et al. / Virology 379 (2008) 197–204phosphorylation could potentially be increased further. Phosphoryla-
tion of eIF2α in mock treated and sal treated Vero cells infected with
the rescuant virus, F(R), were similar to those seen in wild type strain
F-infected cells (data not shown), indicating that the lack of the sal-
dependent increase in eIF2α phosphorylation was due to the ICP34.5
mutation. Similarly, sal did not increase eIF2α phosphorylation
following infection with the Patton ICP34.5 mutants 5e and SUP1
(Fig. 7A, top panel, lanes 15­18 and 7B), and therewas less induction in
SUP1-infected Vero cells than in cells infected with the ICP34.5
rescued virus Volney (compare lanes 16 and 14).
These data suggest that ICP34.5 is necessary for the increase in
eIF2α phosphorylation induced by sal during HSV-1 infection. Taken
together with the previous result that sal inhibits eIF2α depho-
sphorylation in lysates of ICP34.5-transfected cells (Boyce et al., 2005),
this result further suggests that ICP34.5 is a direct target for sal.
ICP34.5 is a component of a high molecular weight phosphatase
complex (He, Gross, and Roizman,1998), and thus sal could potentially
either inhibit ICP34.5 directly, inhibit another protein in the complex,
or disrupt interactions between subunits of the ICP34.5 containing
complex.
Unexpectedly, although the level of eIF2α phosphorylation was
relatively high in mock treated R3616 infected Vero cells, these levels
of phosphorylation were reproducibly reduced by sal treatment
(Fig. 7A and 7B). What causes this surprising reduction? A general
explanation is that sal in combination with the absence of ICP34.5
elicits a response that results in the reduction. One speciﬁc possibility
is that PKR or another eIF2α kinase becomes less activated.
Examination of data in previous reports (Cassady et al., 2002; Chou
et al., 1995; He et al., 1997a) suggests that PKR activation is lower in
certain cells infected with R3616 relative to cells infected with wild
type HSV-1. Additionally, although a more recent report did not
examine the effects of wild-type virus, it suggested that the ICP34.5
mutant virus R3616 does not activate PKR in Vero cells (Smith et al.,
2006). Such lower levels of PKR activation in R3616 infected cells
relative towild type HSV-1 infected cells, along with inhibition of viral
replication, might account for the decrease in eIF2α phosphorylation
upon treatment with sal in R3616 infected Vero cells.
IE US11 expression and the salubrinal-dependent increase in eIF2α
phosphorylation during HSV-1 infection
We also investigated the effects of IE US11 expression on
phosphorylation of eIF2α with or without treatment with sal. The
phosphorylation of eIF2α in mock- and sal-treated NM1- and Volney-
infected Vero cells was comparable to that in Vero cells infected with
their wild type parental viruses, KOS and Patton respectively (Fig. 7A,
top panel, lanes 9 and 10, 13 and 14, and 7B). These data suggest that
immediate early expression of US11 alone does not result in a decrease
in eIF2α phosphorylation. It may be that IE expression of US11 only
transiently reduces eIF2α phosphorylation at early times post-
infection, before it is readily detectable by western blot. Additionally,
eIF2α kinases other than PKR that are not known to be inhibited by
US11, such as PERK or GCN2, may be activated during HSV-1 infection
and account for the relatively high levels of eIF2α phosphorylation in
sal-treated Vero cells infected with the IE US11 viruses NM1 and
Volney.
However, there was less phosphorylation either in the presence or
absence of sal in Vero cells infected with SUP1, which exhibits IE US11
expression, relative to cells infected with 5e, which does not exhibit IE
US11, but contains the same ICP34.5 mutation as SUP1 (Fig. 7A, top
panel, lanes 15–18, and 7B). Thus, in the absence of ICP34.5, IE US11
expression appeared to decrease eIF2α phosphorylation, as expected.
Perhaps during infection with ICP34.5 mutant viruses, PKR is the
predominant eIF2α kinase activated (albeit to a lower level than wild
type virus infection), allowing IE US11 to inhibit the activity of PKR
and preclude the phosphorylation of eIF2α.Relationships between antiviral activity of salubrinal and eIF2α
phosphorylation
The lack of effect of IE US11 expression on eIF2α phosphorylation
in Vero cells in the presence of sal (Fig. 7) is consistent with the IE
US11 viruses not exhibiting resistance to Sal in Vero cells (Fig. 5),
and their rather slight resistance to sal in MEFs (Fig. 4). Additionally,
the dependence on ICP34.5 for induction of eIF2α phosphorylation in
Vero cells by sal (Fig. 7) is consistent with the resistance conferred by
the ICP34.5 mutant SUP1 in MEFs (Fig. 6). It does not, however,
explain, the sensitivity of the ICP34.5 mutant R3616 to salubrinal in
Vero cells. One possible way to explain that result is that the eIF2α
phosphorylation observed in sal treated R3616-infected Vero cells is
sufﬁcient for full antiviral activity. However, that would not explain
the ability of R3616 to replicate in Vero cells, given that this virus
induces even more eIF2α phosphorylation in the absence of sal.
Alternatively, one may invoke an activity of sal that inhibits HSV-1
replication independent of effects on eIF2α phosphorylation. It is
possible that although sal does not globally inhibit dephosphorylation
(Boyce et al., 2005), it may selectively inhibit dephosphorylation
events other than eIF2α, and inhibition of these additional depho-
sphorylationsmay contribute to the activity of sal and thus result in its
ICP34.5-independent antiviral activity. Alternatively, there may be off-
target effects of sal that come into play, and the extent of these non-
speciﬁc effects may differ between different cell types, and may be
more pronounced during infection with ICP34.5 mutant viruses. In
this regard, we note that sal slightly but measurably inhibited HSV-1
replication in MEFs containing a non-phosphorylatable eIF2α (Boyce
et al., 2005). Although we consistently observed a decrease in eIF2α
phosphorylation in R3616 infected Vero cells treated with sal at 14 h
post infection, relative to mock treated Vero cells infected with R3616,
eIF2α is also phosphorylated prior to infection due to pre-treatment
with sal that inhibits GADD34. This phosphorylation may inhibit
expression of viral genes to a degree and thus result in the observed
decrease in plaque formation. Further investigation is needed to
address these possibilities.
This report provides evidence for ICP34.5 as a target for the
antiviral activity of sal in at least some cells and also identiﬁes sal as a
molecular tool that may be useful for studying the activity of ICP34.5
during HSV-1 infection. This report also demonstrates that sal has
ICP34.5-independent activity and cell type speciﬁcity, and thus lays
the groundwork for future studies to further investigate the mechan-
ism of sal activity.
Materials and methods
Cells
African green monkey kidney (Vero) cells (originally from Amer-
ican Type Culture Collection) were maintained in Dulbecco's minimal
essential medium (DMEM) supplemented with 5% newborn calf
serum (NCS), 1% penicillin and streptomycin (P/S), and 1% amphoter-
icin B (amphB). Murine embryo ﬁbroblasts (MEFs, generously
provided by Randal Kaufman) were maintained in DMEM supple-
mented with 10% fetal calf serum, 1% P/S, and 1% amphB.
Plasmids
pKS+ICP27, which contains the ICP27 gene in pBluescript KS+
(Stratagene), was constructed and generously provided by Martha
Kramer in our laboratory. pBS-ICP27prom, which contains the ICP27
promoter, was constructed by digesting pKS+ICP27 with HinfI (all
enzymes from NEB), treating with the Klenow fragment of E. coli DNA
polymerase I (Klenow), digesting with BamHI and ligating the ~326 bp
DNA fragment, containing the ICP27 promoter region, into the SmaI
and BamHI sites of pBluescript II SK+ (Stratagene). pMAL-pp-US11,
203K.F. Bryant et al. / Virology 379 (2008) 197–204which contains the US11 gene, has been previously described (Bryant
et al., 2005). pBS-αUS11, which contains US11 downstream of the
ICP27 promoter, was constructed by ligating the EcoRI–HindIII DNA
fragment containing the US11 gene from pMAL-pp-US11 into the
EcoRI and HindIII sites of pBS-ICP27prom. pAG7.TK.1, which contains
the HSV-1 tk gene in pBluescript II SK+ (Stratagene), was constructed
and generously provided by Anthony Grifﬁths in our laboratory.
pAG7.TK.αUS11, which contains US11 under the control of the ICP27
promoter inserted into the tk gene, was constructed by ligating the
Klenow treated HincII–XbaI DNA fragment from pBS-αUS11 into the
Klenow treated PstI site in pAG7.TK.1. The sequence of the IE US11
cassette in pAG7.TK.αUS11 was conﬁrmed to be correct by DNA
sequencing.
Viruses
Wild type HSV-1 strains KOS, F, and Patton, the ICP34.5 null
mutants R3616 (Chou et al., 1990) and 5e (Mohr and Gluzman, 1996),
the R3616 rescuant F(R) (Chou et al., 1990), the IE US11mutants SUP1
(Mohr and Gluzman, 1996) and Volney (Mohr et al., 2001) and NM1
(described below) were propagated and titrated on Vero cells. Strain F,
R3616, and F(R) were generously provided by Joany Chou and Bernard
Roizman and strain Patton, 5e, Volney, and SUP1 were generously
provided by Ian Mohr.
Plaque reduction assays
Sal was purchased from ChemBridge or synthesized as previously
described (Long et al., 2005) and generously provided by Kai Long and
Dawei Ma. Vero cells or MEFs were treated for 24 h with either the
indicated concentration of sal in a DMSO-containing vehicle, or the
equivalent volume of the DMSO-containing vehicle in normal growth
medium for the cell type. Cells were subsequently infected with
~150 pfu/well of the indicated virus in the presence of the DMSO-
containing vehicle or vehicle containing the indicated concentration
of sal for 1 h in DMEM containing 2% NCS, 1% P/S, and 1% amphB.
Following the 1 h viral adsorption, the inocula were removed and
replaced with DMEM containing methyl cellulose, 2% NCS, 1% P/S, 1%
amphB, and the indicated concentration of sal. Cells were incubated
for 2–3 days to allow plaque formation. When plaques were clearly
visible, infected cell monolayers were ﬁxed with acetone and
methanol (1:1, v:v), stained with crystal violet, and the number of
plaques in eachwell were counted using a dissecting lightmicroscope.
Construction of NM1 mutant virus
The IE US11 mutant virus NM1, which expresses US11 from the
ICP27 promoter inserted into the tk locus, was generated by co-
transfecting infectious KOS viral DNA and pAG7.TK.αUS11 (described
above) that was linearized by digestionwith SacII into Vero cells using
Effectene reagents (Qiagen) according to the manufacturer’s instruc-
tions. Recombinants were selected by replicating progeny virus from
this transfection in the presence of 100 μM acyclovir. NM1 was plaque
puriﬁed three times prior to use in experiments and the presence of
the IE US11 expression cassette in the ﬁnal plaque puriﬁed isolate was
conﬁrmed by PCR followed by sequencing of the PCR product.
Western blotting
Western blotting experiments were performed on samples from
Vero cells grown in 60 mm dishes or 6-well plates. For eIF2αwestern
blots, cells were either treated with 75 μM sal dissolved in DMSO-
containing vehicle or mock treated with an equivalent volume of the
vehicle for 24 h prior to infection at a multiplicity of 3 with the
indicated virus in the presence of the indicated concentration of sal,
and harvested at 14 h post infection. For US11western blots, cells wereinfected at an MOI of 10 with either KOS or NM1 and harvested at the
indicated time. Lysates were prepared by rinsing the monolayers with
phosphate buffered saline, and then the cells were lysed in SDS-PAGE
loading buffer and boiled for 5 min. Polypeptides were resolved by
SDS-PAGE and samples were transferred to a PVDF membrane.
Membranes were blocked for 1 h in 5% milk in TBST prior to reacting
with primary antibodies at 4 °C overnight. The total eIF2α antibody
was from Santa Cruz Biotech, the phospho-Ser51 antibody was from
Cell Signaling Technology, the β-actin antibody was from Abcam, and
the US11 antibody was generated by Promega by immunizing rabbits
with puriﬁed recombinant MBP-US11 prepared by Yun-Sheng He in
our laboratory. All primary antibodies were diluted 1:1000 in 5% milk
in TBST. HRP-conjugated secondary antibodies (Southern Biotech)
were diluted 1:5000 in 5%milk in TBST.Western blots were developed
using ECL reagents (Pierce).
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